EMA Upholds Rejection of Omeros’ Narsoplimab for Transplant Complication
European regulators confirmed a negative opinion on Omeros’ first-in-class TA-TMA therapy despite FDA approval and strong U.S. demand.
European regulators confirmed a negative opinion on Omeros’ first-in-class TA-TMA therapy despite FDA approval and strong U.S. demand.
Labcorp will buy select BioReference clinical, women’s health, and urology assets from OPKO Health for up to $872 million, adding 80+ patient service centers.
LUCENT-2 and VIVID-1 post-hoc data show Omvoh enabled comprehensive disease control and corticosteroid-free deep remission in IBD at one year.
Recursion announces oversubscribed $200M raise, positive Phase 1b/2 FAP data for REC-4881, early REC-1245 activity, and Sanofi option milestone.
Landmark NEJM study shows Dexcom G7 reduces A1C and boosts time in range for non-insulin Type 2 diabetes patients, lifting shares.
The program is now on hold.